Article
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
Leukemia - 1 Jul 2019
Haase Detlef, Stevenson Kristen E, Neuberg Donna, Maciejewski Jaroslaw P, Nazha Aziz, Sekeres Mikkael A, Ebert Benjamin L, Garcia-Manero Guillermo, Haferlach Claudia, Haferlach Torsten, Kern Wolfgang, Ogawa Seishi, Nagata Yasunobu, Yoshida Kenichi, Graubert Timothy A, Walter Matthew J, List Alan F, Komrokji Rami S, Padron Eric, Sallman David, Papaemmanuil Elli, Campbell Peter J, Savona Michael R, Seegmiller Adam, Adès Lionel, Fenaux Pierre, Shih Lee-Yung, Bowen David, Groves Michael J, Tauro Sudhir, Fontenay Michaela, Kosmider Olivier, Bar-Natan Michal, Steensma David, Stone Richard, Heuser Michael, Thol Felicitas, Cazzola Mario, Malcovati Luca, Karsan Aly, Ganster Christina, Hellström-Lindberg Eva, Boultwood Jacqueline, Pellagatti Andrea, Santini Valeria, Quek Lynn, Vyas Paresh, Tüchler Heinz, Greenberg Peter L, Bejar Rafael
Abstract excerpt
Risk stratification is critical in the care of patients with myelodysplastic syndromes (MDS). Approximately 10% have a complex karyotype (CK), defined as more than two cytogenetic abnormalities, which is a highly adverse prognostic marker. However, CK-MDS can carry a wide range of chromosomal abnormalities and somatic mutations. To refine risk stratification of CK-MDS patients, we examined data from 359 CK-MDS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.